Cervical Cancer Organoids Test a PARP–BLM Combination After DNA-Repair Profiling
Neuroendocrine cervical cancer organoids show moderate olaparib sensitivity. Combining olaparib with BLM inhibition reduced ATP-based viability more than either agent alone; cell and fibroblast studies implicated E2F1–BLM signaling in resistance.
From a Rare Cancer Cohort to a Repair Hypothesis
A multicenter study led by Fujian Medical University and collaborating clinical and academic institutions investigated why neuroendocrine cervical carcinoma (NECC) responds poorly to standard chemotherapy. The researchers combined patient cohorts, paired tumor profiling, cancer cell lines, patient-derived organoids and mouse xenografts. The organoids provided a human three-dimensional setting for comparing candidate interventions emerging from the molecular analyses.
The original collections comprised 715 NECC and 1,059 non-NECC cases. After propensity-score matching, the chemotherapy analysis included 112 NECC and 207 non-NECC patients. NECC was associated with higher mortality, with a hazard ratio of 5.17 (95% CI 3.15–8.49). Within the NECC cohort, the platinum–taxane and etoposide–cisplatin regimens were not associated with a statistically significant survival improvement over no chemotherapy. The observational comparison motivated investigation of alternative vulnerabilities.
Active Repair Creates a Candidate Dependency
Transcriptomic, proteomic and phosphoproteomic profiling of tumor and matched adjacent tissue from 10 NECC patients implicated heightened DNA replication and homologous recombination repair (HRR). BLM helicase, RAD51 and MCM-related activity were prominent. A reporter assay confirmed greater HRR activity in TC-YIK NECC cells than in the SiHa and HeLa comparators. NECC cells and organoids also showed elevated replication-stress markers.
This finding led the authors to investigate poly(ADP-ribose) polymerase (PARP) inhibition despite the absence of a common HRR-deficient phenotype. TC-YIK cells had an olaparib IC50 of 2.6 μM, while the highly sensitive ovarian comparator A2780 had an IC50 of 0.72 μM. The NECC response was therefore moderate within the tested panel. Combining olaparib with platinum agents did not produce strong synergy in TC-YIK; the reported cisplatin combination ZIP score was 3.725.
BLM abundance offered a potential explanation for the limited response. Increasing BLM expression reduced olaparib sensitivity, whereas BLM knockdown increased it. The BLM inhibitor ML216 combined with olaparib produced a ZIP synergy score of 19.349 in TC-YIK cells. DNA-damage and repair-marker measurements supported impaired repair under the dual intervention.
What the Organoid Comparisons Measured
The organoid experiments compared adenosine triphosphate (ATP)-based viability after drug exposure, supported by bright-field imaging and molecular staining. Olaparib IC50 was 7.47 μM in NECC organoids and exceeded 50 μM in a cervical adenosquamous organoid comparator. Combining olaparib with ML216 reduced ATP viability more than either agent alone. The ZIP synergy values came from the cell-line experiments; the organoid evidence was a separate viability comparison.
The methods describe three technical replicates per concentration or condition. Dose-response profiling used olaparib at 0.1–50 μM over 48 hours. A separate combination-validation experiment used 500 μM olaparib and 500 μM BLM inhibitor. The combination measurements were obtained at higher concentrations than those used for the olaparib potency curves. The organoid experiments report technical replicate wells without establishing a multi-donor response distribution.
Fibroblasts Reveal an Additional Resistance Context
The investigators traced BLM regulation to the transcription factor E2F1. Promoter-binding experiments and E2F1 knockdown supported direct transcriptional control. Cancer-associated fibroblast coculture increased E2F1 and BLM expression in TC-YIK cells, promoted proliferation and weakened olaparib response. BLM depletion or inhibition counteracted this protection. Cytokine profiling implicated IL-6 in the fibroblast interaction, although the authors identify the detailed upstream mechanism as unresolved.
In mouse xenografts, olaparib plus ML216 suppressed tumor growth more strongly than either treatment alone and retained activity in fibroblast-rich grafts. The cotransplantation experiment included seven mice per treatment arm. Body-weight and organ-histology observations did not reveal obvious injury under these conditions, providing a limited preclinical tolerability observation.
Functional work relies heavily on TC-YIK, the organoid collection is limited, and the clinical cohorts were Han Chinese. The authors call for broader organoid testing and development of clinical-grade BLM inhibitors before advancing the combination. In the present cell comparison, adding platinum did not strongly enhance olaparib activity.